WO1993001833A1 - Improved vaccine - Google Patents
Improved vaccine Download PDFInfo
- Publication number
- WO1993001833A1 WO1993001833A1 PCT/AU1992/000363 AU9200363W WO9301833A1 WO 1993001833 A1 WO1993001833 A1 WO 1993001833A1 AU 9200363 W AU9200363 W AU 9200363W WO 9301833 A1 WO9301833 A1 WO 9301833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- domain
- rabies
- rhabdovirus
- paramyxovirus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 239000002245 particle Substances 0.000 claims abstract description 50
- 206010037742 Rabies Diseases 0.000 claims abstract description 47
- 241000700605 Viruses Species 0.000 claims abstract description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 35
- 108091006027 G proteins Proteins 0.000 claims abstract description 27
- 108091000058 GTP-Binding Proteins 0.000 claims abstract description 27
- 102000030782 GTP binding Human genes 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 19
- 239000000945 filler Substances 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims abstract description 18
- 108010081734 Ribonucleoproteins Proteins 0.000 claims abstract description 13
- 102000004389 Ribonucleoproteins Human genes 0.000 claims abstract description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 12
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 210000004779 membrane envelope Anatomy 0.000 claims abstract description 6
- 239000011159 matrix material Substances 0.000 claims abstract description 4
- 101710085938 Matrix protein Proteins 0.000 claims abstract 2
- 101710127721 Membrane protein Proteins 0.000 claims abstract 2
- 108020004414 DNA Proteins 0.000 claims description 65
- 241000701447 unidentified baculovirus Species 0.000 claims description 62
- 102000053642 Catalytic RNA Human genes 0.000 claims description 35
- 108090000994 Catalytic RNA Proteins 0.000 claims description 35
- 108091092562 ribozyme Proteins 0.000 claims description 35
- 241000711798 Rabies lyssavirus Species 0.000 claims description 22
- 102000053602 DNA Human genes 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 18
- 241000206602 Eukaryota Species 0.000 claims description 15
- 101710141454 Nucleoprotein Proteins 0.000 claims description 9
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 101710172711 Structural protein Proteins 0.000 claims description 5
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 108091027544 Subgenomic mRNA Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 13
- 230000007017 scission Effects 0.000 description 13
- 241000711975 Vesicular stomatitis virus Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000013600 plasmid vector Substances 0.000 description 10
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 9
- 230000009977 dual effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000238631 Hexapoda Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 238000010276 construction Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 241000991587 Enterovirus C Species 0.000 description 5
- 108060003393 Granulin Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101710182846 Polyhedrin Proteins 0.000 description 3
- 241000256248 Spodoptera Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 108010087302 Viral Structural Proteins Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000712462 Bovine ephemeral fever virus Species 0.000 description 2
- 241000712083 Canine morbillivirus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000711897 Rinderpest morbillivirus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 241000724256 Brome mosaic virus Species 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 210000003967 CLP Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000711513 Mononegavirales Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101900236200 Rabies virus Nucleoprotein Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000709710 Swine vesicular disease virus Species 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150038575 clpS gene Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108700010867 paramyxovirus proteins Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LNKSLLXPNOTUHF-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;dodecyl sulfate Chemical compound [Na+].OCC(N)(CO)CO.CCCCCCCCCCCCOS([O-])(=O)=O LNKSLLXPNOTUHF-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- IMPROVED VACCINE TECHNICAL FIELD relates to an improved vaccine, and in particular to vaccines for treatment of infections caused by rhabdoviruses which include rabies virus, bovine ephemeral fever virus (ie BEFV) and vesicular stomatitis virus (ie VSV), and paramyxoviruses which include mumps virus and measles virus of humans, respiratory syncytial viruses of humans and cattle, rinderpest virus of cattle, canine distemper virus of dogs, Newcastle disease virus of chickens and various parainfluenza viruses.
- Rabies is a disease of the central nervous system of major importance to human and veterinary medicine. The disease causes a fatal encephalomyelitis for which there is no treatment once the disease symptoms have appeared. Vaccination either before or after virus contamination is then the only way to combat the infection. Various vaccines are licensed for human, veterinary and domestic animal use and all are prepared from killed virus. To date, subunit vaccines have not been used commercially.
- Rabies virions contain a ribonucleoprotein (RNP) consisting of a negative stranded (-) RNA molecule approximately 12,000 nucleotides long surrounded by a protective sheath of N protein.
- RNP ribonucleoprotein
- the RNP is associated with two other proteins (L and M ⁇ ) and together this structure forms the transcription complex.
- the transcription complex is surrounded by a lipid bilayer membrane associated with 2 proteins which comprise a transmembrane glycoprotein (G) and an internal matrix protein (M 2 ).
- G protein forms the spikes visible on the surface of virions.
- rhabdoviruses and paramyxoviruses have a similar structure, although the number and function of the proteins can be different.
- the foregoing synopsis on rabies will be found in Prehaud et al (1989) Virology 173: 390-399 and Prehaud et al (1990) Virology 178: 486-497.
- a .summary of the structure of some other rhabdoviruses and paramyxoviruses will be found in The Rhabdoviruses (1987) Ed. RR Wagner Plenum Press, New York; Emerson (1985) in Virology Ed.
- Types of vaccine that have been developed or considered as candidates include the following:
- Live attenuated vaccines These vaccines have been used for the oral vaccination of wildlife animals. For such purposes it is a prerequisite that candidate vaccines are avirulent for both the target species and for the non-target animals that may be occasionally infected.
- the candidate live vaccine has also to be immunogenic and genetically stable.
- new attenuated virus strains have been prepared having several mutations that affect virulence.
- Recombinant poxyiruses include recombinant fowlpox virus and recombinant vaccinia virus. Both have been shown to be effective vaccines. However, it is not known whether release into the environment of live recombinant poxviruses poses other risks for wildlife.
- Subunit proteins or structures Vaccines derived from subunit proteins or structures of the virus have been proposed. However, the cost of these vaccines is high.
- subunit vaccine include G-M 2 complexes, as described in Benmansour (1985) Ann. Inst. Pasteur Virol. 136E:167-173, and immunostimulating complexes (ISCOMs) described in Morein et al. (1984) Nature (Lond.) 308:457- 460.
- Liposome vaccines have been described in Perrin et al (1985) Dev. Stand. Biol. 160: 483-491, and vaccines based on ribonucleoproteins have been described in Dietzschold et al.
- VSV virus contains 5 structural proteins and that each of these proteins plays a role in the replication, assembly and budding of VSV. These include the nucleocapsid protein (N), the phosphoprotein ( S), and the large polymerase protein (L) which with the viral RNA genome form a RNP transcription complex similar to that described above for rabies virus. There is also included a glycoprotein (G) which forms the spikes on the viral envelope and which interacts with receptors on susceptible cells. There is also a matrix protein (M) which appears to be similar to the M 2 protein of rabies virus and is thought to assemble at the inner surface of the cellular plasma membrane to allow association with the G protein and the RNP complex during particle morphogenesis.
- N nucleocapsid protein
- S phosphoprotein
- L large polymerase protein
- G glycoprotein
- M matrix protein
- VSV infects horses, cattle, swine as well as humans and previous vaccines have been derived from inactivated or killed virus or attenuated virus as described above in relation to conventional rabies vaccines.
- the same problems in relation to possible conversion from avirulent to virulent forms is also relevant to VSV vaccines.
- Subunit vaccines have not been extensively investigated although immunity may be obtained through a subunit vaccine based on the G protein
- this virus causes an acute infection of cattle and water buffalo.
- Vaccines that have been produced so far include live attenuated viruses or inactivated whole virus. Such vaccines have so far not proved to be commercially successful and also suffer from the risks of incomplete inactivation or reversion to virulence as describe above.
- BEFV as described in
- 61356/90 refers to the use of a subunit vaccine based on the G protein. However, such a vaccine has not been produced commercially.
- Paramyxoviruses and rhabdoviruses are both classified as virus Families (Paramyxoviridae and Rhabdoviridae respectively) in the Order Mononegavirales. These Families of viruses share broadly similar structures, genome organisation and strategies of gene expression and replication. Viruses of both Families have a single-stranded (-) sense RNA genome which incorporates 3' and 5' terminal domains which are involved in nucleation of particle assembly, and at least 5 viral genes including those encoding a nucleoprotein, matrix protein, polymerase protein, glycoprotein and an RNA-dependent RNA polymerase. These corresponding proteins have the same general role in viral replication in both Families.
- - single-stranded
- paramyxovirus particles involves an RNP complex which associates with a matrix protein and buds through the cellular plasma membranes to incorporate glycoproteins in a similar process to that described above for rabies virus.
- Paramyxoviruses include important human and veterinary pathogens including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial viruses, Newcastle disease virus of chickens, rinderpest virus and canine distemper virus.
- pathogens including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial viruses, Newcastle disease virus of chickens, rinderpest virus and canine distemper virus.
- Various inactivated, live attenuated, recombinant and subunit protein vaccines against paramyxoviruses have been described and these have similar properties to those described above for rhabdovirus vaccines.
- VLPs virus-like particles
- Urakawa et al. (1989) J. Gen. Virol 70: 1453-1463 have reported the insertion of the complete polycistronic mRNA of poliovirus in the baculovirus polyhedrin gene.
- Insect cells infected with the -recombinant baculovirus have synthesised and processed the poliovirus polyprotein and generated large quantities of empty VLPs.
- These synthetic capsids contained no RNA and were not infectious but were otherwise similar to native poliovirus.
- infectious cDNA has been cloned into plasmid vectors containing promoters suitable for expression in eukaryote cells. Transfection of eukaryote cells with such vectors has resulted in the production of infectious virus.
- This general approach has been used in relation to a number of viruses of humans, plants and animals including poliovirus [Racaniello and Baltimore (1981) Science 214:916-919], Sindbus virus [Rice et al (1987) J. Virol. 61:3809], swine vesicular disease virus [Inoue et al (1990) J. Gen.
- the process of the invention therefore includes the following steps:
- the DNA molecule may comprise a 3' domain and at least one ribozyme domain and optionally a 5' domain and may incorporate cohesive ends;
- step (1) inserting the DNA obtained in step (1) into the cloning site of a eukaryote expression vector and transfecting a eukaryote cell with the vector containing the genome construct and simultaneously transfecting the same eukaryote cell with vectors containing cloned genes of rhabdovirus or paramyxovirus structural proteins including those with similar functions to the G protein, N protein, M ⁇ protein and M 2 protein of rabies virus; and
- VLPs virus-like particles
- FIG. 1 A general structure for a range of suitable DNA constructs for use in the invention is illustrated in Figure 1 and the general process of the production of the desired VLPs is summarised schematically in Figure 2.
- the 5' and 3' domains may be derived from the sequences of the 5' and 3' non-coding regions of the genome of a rhabdovirus or paramyxovirus although the 5' domain may be deleted if necessary.
- the ribozyme domain or domains may be constructed from any of the known ribozyme structures, some of which are described by Haseloff and Gerlach (1988) Nature 334:585-591.
- the ribozyme domain(s) will ensure that, in step (ii) of the process, extraneous parts of the RNA genome construct transcribed in eukaryote cells [such as vectors sequences and a poly(A) tail] will be cleaved at the appropriate location in the molecule to allow particle assembly [as described in step (iii)] .
- the ribozyme domains may be cleaved from the RNA transcript before assembly into VLPs or included in the transcript provided it does not prevent the assembly process.
- Each of the ribozyme domains may be located externally of the 3' and 5' domains and intervening nucleotide sequences may be interposed between the domains of the construct.
- the ribozyme domain(s) may be located internally of the 3' and 5' domains as shown in Figure 1.
- the filler domain may constitute any nucleotide sequence that has characteristics which will not prevent the formation of VLPs.
- the filler domain will constitute a fragment derived from a portion of the L protein coding region of a rhabdovirus of paramyxovirus which is adjacent to the 5' terminal non-coding region of the (-) RNA genome.
- the filler domain will ensure that the genome to be expressed in step (iii) will be sufficient size (greater than approximately 1000 nucleotides) to allow formation of VLPs.
- DNA constructs suitable for formation of rabies VLPs are illustrated in Figures 3-8.
- DNA sequences which are shown in illustrations are presented as single-stranded molecules in the sense in which the construct will be transcribed. Double-stranded DNA molecules that may be required in certain ' constructs will incorporate a second strand of anti-complementary sequence.
- Figures 3, 4 and 5 illustrate the structural organisation and sequence of a suitable DNA construct (TB-2) which includes two ribozyme domains (Rl and R2).
- the 5' and 3' domains are derived from the known nucleotide sequence of the 5' and 3' terminal regions of the genome of rabies virus (PV and CVS strains).
- the Rl domain is designed to target a site within the (-) RNA transcript of the TB-2 DNA construct.
- the Rl ribozyme in the transcript will cleave the RNA to ensure that extraneous parts of the transcript are removed so that the 5' terminus of the transcript corresponds to that of the 5' terminus of the rabies virus genome.
- the R2 ribozyme domain is designed to target a site within the (-) RNA transcript of the TB-2 DNA construct.
- the R2 ribozyme will cleave the RNA to ensure that extraneous parts of the 3' region of the transcript (including the R2 domain) are removed so that the 3' terminus of the transcript approximates that of the 3' terminus of the rabies virus genome.
- the filler domain in the TB-2 construct is derived from the known nucleotide sequence of a 1135 nucleotide region at the 5' end of the rabies virus (CVS strain) L protein gene.
- Figures 6, 7 and 8 illustrate organisation and sequence of a suitable DNA construct (TB-1) which incorporates a single ribozyme domain (R).
- the 5' and 3' domains are derived from the known nucleotide sequence of the corresponding 5' and 3' terminal regions of the genome of rabies virus (PV and CVS strains).
- the R Ribozyme domain is designed to target a site within the (-) RNA transcript of the TB-1 DNA construct. The R ribozyme will cleave the RNA to ensure that extraneous parts of the 3' region of the transcript (including the R domain) are removed so that the 3' terminus of the transcript approximates that of the 3' terminus of the rabies virus genome.
- the filler domain in the TB-1 construct is derived from the nucleotide sequence of a 1167 nucleotide region at the 5' end of the rabies virus (CVS strain) L protein gene.
- any suitable vector may be used to express the modified genome or genome fragment and viral structural proteins.
- This may include, for example, eukaryote systems, eg mammalian cells using poxvirus, papillomavirus or retrovirus vectors or in yeast cells.
- the preferred expression system is, however, the use of a baculovirus vector to infect an insect host cell such as that from Spodoptera frugiperda.
- Baculoviruses are large DNA viruses which infect insects. Late in the infection cycle baculoviruses express several proteins in very large quantities. The genes that express these proteins (eg polyhedrin and plO) are not essential for baculovirus replication in culture and have been used as cloning sites for foreign genes. Such recombinant baculoviruses express foreign eukaryote or viral proteins in high levels and in a form which often closely resembles the native protein.
- virus proteins have been expressed in the baculovirus system under the control of the plO or polyhedrin promoters.
- Examples of the application of the baculovirus system for expression of viral proteins are provided in Emery (1991) Reviews in Medical Virology 1:11-17.
- Examples of the use of the baculovirus system for expression of rhabdovirus proteins have been provided in Bailey et al (1989) Virology 169: 323-331, Prehaud et al (1989) Virology 173:390-399 and Prehaud et al.
- rabies G protein gene was cloned and inserted into a baculovirus transfer vector pAcYMl derived from the baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV).
- AcNPV Autographa californica nuclear polyhedrosis virus
- the recombinant transfer vector and AcNPV DNA were used to co-transfect Spodoptera frugiperda cells and a recombinant baculovirus which expressed high levels of the rabies G protein was recovered from the cells.
- baculovirus expression vector (AcNPV3) derived from Autographa californica nuclear polyhedrosis virus and containing the complete coding region of the N protein of rabies virus.
- the rabies gene was placed under the control of the AcNPV polyhedrin promoter and was expressed in high levels by the derived recombinant baculovirus in Spodoptera frugiperda cells.
- the baculovirus expression system is also reported in, for example, Smith et al. (1985) Proc. Natl. Acad. Sci. USA 82:8404-8408; Miller et al.
- DI particles may contain all viral structural proteins but contain a deleted and hence defective genome. The defective genome renders the DI particles incapable of replication in the absence of complete, non-defective virus. Aspects relating to the nature of DI particles are reviewed in Huang and Baltimore (1977) Comprehensive Virology 10:73-116; Holland et al (1980) Comprehensive Virology 16:137-192; Perrault (1981) Curr. Top. Microbiol.
- VSV DI particles can occur when cells are infected simultaneously with VSV DI particles and vaccinia virus vectors which expresses all 5 VSV structural proteins from cloned cDNA.
- VLPs synthetic rhabdovirus or paramyxovirus defective or infectious virus-like particles
- VLPs synthetic rhabdovirus or paramyxovirus defective or infectious virus-like particles
- the VLPs may be utilised as a suitable vaccine in combination with suitable adjuvants as is known in the art.
- adjuvants include Quil A and other saponins, ISCOMs, Freund's incomplete or complete adjuvant, and any other adjuvant as described for example in Vanselow (1987) Vet. Bull 57:881-896.
- VLPs will contain all of the important immunogenic proteins of the native virus presented in a form which closely resembles the native structure.
- the VLPs When used in a vaccine for administration to subjects who may suffer from a disease or complaint caused by rhabdoviruses or paramyxoviruses, the VLPs will cause immunity in much the same way as vaccines incorporating inactivated viruses are presently used.
- vaccines incorporating rhabdovirus or paramyxovirus particles there is no possibility that infectious virus will be present or that reversion to virulence will occur because the VLPs of the present invention may use only a fragment of the viral genome and no genes encoding complete viral proteins.
- the principles and strategies described for construction VLPs based on rabies virus may be applied to any other (-)sense non- segmented RNA virus, particularly rhabdoviruses and paramyxoviruses.
- the required VLP will contain a suitable modified genome or genome fragment containing essential assembly elements including a 3' domain, corresponding to the 3' terminal sequence of the genome of the rhabdovirus or paramyxovirus, at least one ribozyme domain to ensure that the expressed RNA is cleaved to produce the required 3' terminus and a filler domain to ensure that the expressed sub-genomic RNA has sufficient size to nucleate particle formation (approximately 1000 nucleotides).
- the construct may also incorporate a 5' domain which will perfectly or imperfectly base pair with the 3' domain and a second ribozyme domain to ensure that the expressed RNA is cleaved to produce the required 5' terminus.
- the transcript of the required DNA construct will then be co- expressed in eukaryote cells with the required structural proteins of the homologous rhabdovirus or paramyxovirus to all VLP formation.
- BEFV Bovine ephemeral fever virus cDNA Complementary deoxyribonucleic acid Core-like particles Challenge virus standard Defective-interfering Deoxyribonucleic acid Ethylynediamine-tetraacetic acid Polyacrylamide gel electrophoresis Phosphate buffered saline Polymerase chain reaction Plaque forming unit Phenylmethylsulphonyl fluoride Polyadenylic acid Pasteur virus Sodium dodecyl sulphate Tris(hydroxymethyl) aminomethane Ribozyme domain of TB-1 DNA construct Ribozyme 1 domain of TB-2 DNA construct Ribozyme 2 domain of TB-2 DNA construct Ribnucleic acid Ribonucleoprotein Revolutions per minute Room temperature Vesicular stomatitis virus Virus-like particle Percentage by weight MATERIALS AND GENERAL EXPERIMENTAL PROCEDURES
- Synthetic oligonucleotides (see Figure 9) were supplied as deprotected and purified products by the Centre for Molecular Biology and Biotechnology, St Lucia, Brisbane, Australia.
- the TB-2 DNA is constructed by several consecutive PCRs by using overlapping synthetic oligonucleotide primers and a rabies genomic RNA template in the following steps:
- a plasmid vector containing the filler domain was obtained by using the rabies virus (CVS strain) genome, primer LI ( Figure 9) and reverse transcriptase to prepare a single- stranded cDNA copy of the required portion of the rabies L protein gene and then by using primers LI and L2 ( Figure 9) and the polymerase chain reaction (PCR) to amplify a double- stranded DNA molecule of the required nucleotide sequence.
- the DNA molecule was then cloned into the Sma I site of a suitable plasmid vector (eg. pUC118).
- the recombinant plasmid containing the filler domain was named pFILL.
- the complete nucleotide sequence of the recombinant DNA insert in pFILL was determined and shown to correspond to that of the filler domain illustrated in Figure 5.
- the filler domain was extended by PCR using primers TB5A and TB3A ( Figure 9) and pFILL obtained in step (i) as template.
- the PCR product obtained in step (ii) was extended by PCR using primers TB5B and TB3B ( Figure 9).
- the PCR product obtained in step (iii) was extended by PCR using primers TB5C and TB3C ( Figure 9).
- step (v) The PCR product obtained in step (iv) was cloned after BAh HI digestion in a suitable plasmid vector (eg pBluescript KS+, Stratagene,
- the plasmid vector containing the TB-2 construct was named pTB2.
- the complete nucleotide sequence of the recombinant insert in pTB2 was determined and shown to correspond to that of the TB-2 construct illustrated in Figure 5.
- Example 2 Construction of a plasmid vector containing the TB-1 DNA molecule.
- the TB-1 DNA was derived from the TB-2 DNA construct by using PCR according to the following steps: (i) The pTB-2 plasmid was used as a template for PCR using primers TB1 and TB3C ( Figure 9).
- step (ii) The PCR product obtained in step (i) was extended by PCR using primers TB5C and TB3C
- step (iii) The PCR product obtained in step (ii) was cloned after Bam HI digestion in a suitable plasmid vector (eg pBluescript KS+, Stratagene, La Jolla, USA).
- the plasmid vector containing the TB-1 construct was named pTBl.
- the complete nucleotide sequence of the recombinant insert in pTBl was determined and shown to correspond to that of the TB-1 DNA construct illustrated in Figure 8.
- Example 3 In v rotranscription of TB-2 and TB-1 RNA and demonstration of ribozyme cleavage.
- Plasmid vectors pTB2 and pTBl were cut with Xbal or uncut, and were used as templates for in vitro transcription by T3 RNA polymerase using the pGEM express transcription kit (promega, Rozelle, NSW, Australia) and [ S]UTP (Amersham International Ltd). In vitro transcriptions were conducted at 37 C C or at 28°C. The products were analysed by electrophoresis in 6% polyacrylamide-urea sequencing gels. A plasmid of known sequence was prepared in a standard dideoxynucleotide sequencing reaction and run in adjacent lanes as a molecular weight ladder. After electrophoresis, the gels were fixed and dried and visualised by autoradiography.
- RNA transcripts that were of a size corresponding to the products of cis-acting cleavage at the sites targeted by the ribozyme domains.
- the results are illustrated in Figure 10 for transcription from plasmid pTB2 at 37°C.
- the short product of ribozyme Rl cleavage at the 5' end of the transcript appeared as a discrete band (A) of 93 nucleotides corresponding to the predicted sequence from the T3 transcription start to the Rl cleavage site.
- Baculovirus (AcNPV) transfer vectors were constructed by obtaining the TB-2 and TB-1 DNA inserts from recombinant plasmids pTB2 and pTBl respectively by digestion with Bam Hi, and subcloning into a Bam HI digested, dephosphorylated derivative of the transfer vector pAcYMl (NERC IVEM, Oxford, UK).
- the transfer vectors containing the TB-2 and TB-1 DNA inserts were named pAcTB2 and pAcTBl respectively.
- recombinant baculoviruses expressing the TB-2 and TB-1 subgenomic RNAs Spodoptera frugiperda cells were lipofected with a mixture of recombinant transfer vector (pAcTB2 or pAcTBl) DNA (1 ⁇ g) and baculovirus AcRP23-lacZ viral DNA (100 ng).
- the recombinant baculoviruses were selected as described previously (Kitts et al. 1990, Nucleic Acid Research 18:5667-5672; and Prehaud et al. 1992, Virology, in Press) and high titers stocks were prepared (i.e. >10 PFU/ml).
- the recombinant baculoviruses containing the TB-2 and TB-1 DNA constructs were names Ac.TB2 and Ac.TBl respectively.
- Example 5 Mixed infections of Spodoptera frugiperdacells and purification of rabies VLPs.
- RNA AC.TB2 or Ac.TBl
- AcNPV3 Ml protein (AcNPVMl), M2 protein (AcNPVM2) and G protein (AcNPV2) (see
- RNA (AC.TB2 or Ac.TBl). The cultures were incubated for 3 days at 38D.
- the culture supernatants were recovered from the cultures and clarified by a centrifugation at 4,000 rpm for 10 min at 4 in a JA20 rotor (Beckman). Particles were pelleted from the supernatant in an SW28 roto (Beckman) for lh at 27,000 rpm at 4°C. The pellet were resuspended in TD buffer (0.8 mM TrisOHCl, 150m,M NaCl, 5 mM KCl, 0.7 mM
- Example 6 Preparation of cell lysates from mixedly-infected Spodoptera frugiperdacells .
- Spodoptera frugiperda cells 1.5 x 10 cells
- PBS phosphate-buffered saline
- RIPA buffer 1% Triton X-100, 1% sodium dodecyl sulphate, pH 7.4
- Cell lysate preparations obtained as described in Example 6 above and gradient-purified particle preparations from the culture supernatant described in Example 5 above were analysed for the presence of rabies virus proteins by SDS-PAGE and immunoblotting. Proteins resolved by electrophoresis in a 10% SDS-polyacryulamide gel were electroblotted to a nitrocellulose membrane. Blots wee incubated for 2 h with the blocking solution (3% low fat skim milk powder and 0.01% sodium azide in PBS), then transferred to blocking solution containing a 1/500 dilution of a mouse anti-CVS polyclonal antibody and incubated overnight.
- the blocking solution 3% low fat skim milk powder and 0.01% sodium azide in PBS
- the bound antibody was detected using a peroxidase-conjugated anti- mouse IgG (Sigma Chemicals, St. Louis, MO, USA).
- the blots were developed by using 4-chloro-l-napthol and 3- 3'-diaminobenzidine tetrahydrochloride (Sigma Chemicals, St Louis, MO, USA) as substrate for the peroxidase.
- the invention also includes within its scope the aforementioned DNA constructs per se as well as the VLPs which may also be used for purposes other than a vaccine component ie. diagnostic reagent.
- FIGURE 1 Schematic illustration of some DNA constructs that would be suitable for expression of a sub-genomic RNA of a rhabdovirus or paramyxovirus for inclusion in VLPs.
- Rl and R2 are suitable ribozyme domains; the 5' domain is derived from the 5' terminal sequence of a rhabdovirus or paramyxovirus (-) sense RNA genome; the 3' domain is derived from the 3' terminal sequence of a rhabdovirus or paramyxovirus (-) sense RNA genome; the filler domain is any suitable sequence of nucleotides; Fl and F2 are parts of the filler domain; and SI and S2 are intervening nucleotide sequences.
- FIGURE 2 Schematic illustration of the general process of rhabdovirus or paramyxovirus VLP formation using for example the formation of rabies VLPs using the baculovirus expression system.
- FIGURE 3 Schematic illustration of the organisation of the TB-2 sub-genomic DNA construct.
- the structure is represented as a double-stranded DNA molecule which is suitable for cloning into the Bam HI site of a baculovirus expression vector.
- the Rl and R2 ribozyme cleavage sites are those which are active in the RNA transcript of this cloned DNA assuming transcription occurs in the direction indicated.
- FIGURE 4 Illustration of the sequence of the transcript of the TB-2 sub-genomic DNA construct indicating the functional domains and the Rl and R2 ribozyme cleavage sites.
- FIGURE 5 Nucleotide sequence of the TB-2 sub- genomic DNA construct (single-stranded DNA in the transcription [+] sense).
- FIGURE 6 Schematic illustration of the organisation of the TB-1 sub-genomic DNA construct.
- the structure is represented as a double-stranded DNA molecule which is suitable for cloning into the Bam HI site of a baculovirus expression vector.
- the R ribozyme cleavage site are those which are active in the RNA transcript of this cloned DNA assuming transcription occurs in the direction indicated.
- FIGURE 7 Illustration of the sequence of the transcript of the TB-1 sub-genomic DNA construct indicating the functional domains and the R ribozyme cleavage site.
- FIGURE 8 Nucleotide sequence of the TB-1 sub- genomic DNA construct (illustrated as a single-stranded DNA in the transcription [+] sense).
- FIGURE 9 Nucleotide sequence of synthetic oligonucleotides used for PCR in the construction of the filler domain, the TB-2 sub-genomic DNA and the derived TB-1 sub-genomic DNA.
- FIGURE 10 Autoradiograph of a 6% polyacrylamide- urea gel indicating the products of in vitro transcription of uncut and Xba I-cut pTB2 DNA at 37°C using T3 RNA polymerase. Ribozyme cleavage products are identified as bands A, B and C as described in the text above.
- FIGURE 11 Immunoblot of cell lysates and particle preparations from mixed infections with recombinant baculoviruses using polyclonal anti-rabies mouse serum as described in the text above.
- Lane 1 Lysate of cells infected with wild type AcNPV
- Lane 2 Lysate of cells infected with recombinant dual expression baculoviruses expressing rabies N/Ml proteins and M2/G proteins
- Lane 3 Lysate of cells infected with recombinant single expression baculoviruses expressing rabies N, Ml, M2 and G proteins
- Lane 4 Particles prepared from the culture supernatant of cells infected with recombinant dual expression baculoviruses expressing rabies N/Ml proteins and M2/G proteins and recombinant baculovirus AcTB2 containing the TB-2 DNA construct
- Lane 5 Particles prepared from the culture supernatant of cells infected with recombinant dual expression baculoviruses expressing rabies N/Ml proteins and M2/G proteins.
- FIGURE 12 Electron micrograph of rabies VLP preparation.
- the sample was prepared as described in the text above from the culture supernatant obtained from a mixed infection of Spodoptera frugiperda cells with recombinant baculovirus vectors expressing the rabies N, Ml, M2 and G proteins and a recombinant baculovirus expression vector Ac.TB2.
- the micrograph illustrates both rabies VLPs (irregular particles 70-85 nm diameter, with surface projections) and particles of the recombinant baculoviruses (rod-shaped particles 40 x 250 nm).
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5502485A JPH06509228A (en) | 1991-07-17 | 1992-07-17 | improved vaccines |
EP92916278A EP0595970A4 (en) | 1991-07-17 | 1992-07-17 | Improved vaccine. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPK725891 | 1991-07-17 | ||
AUPK7258 | 1991-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993001833A1 true WO1993001833A1 (en) | 1993-02-04 |
Family
ID=3775548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1992/000363 WO1993001833A1 (en) | 1991-07-17 | 1992-07-17 | Improved vaccine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0595970A4 (en) |
JP (1) | JPH06509228A (en) |
CA (1) | CA2113572A1 (en) |
NZ (1) | NZ243611A (en) |
WO (1) | WO1993001833A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0672153A1 (en) * | 1992-09-28 | 1995-09-20 | Commonwealth Scientific And Industrial Research Organisation | Vector to deliver and express foreign gene |
WO1999061639A2 (en) * | 1998-05-22 | 1999-12-02 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
EP1219705A1 (en) * | 2000-12-29 | 2002-07-03 | Evotec OAI AG | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
US6818209B1 (en) | 1998-05-22 | 2004-11-16 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
US7419802B2 (en) | 1999-06-30 | 2008-09-02 | Evotec Ag | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
WO2008124636A1 (en) | 2007-04-04 | 2008-10-16 | Weatherford/Lamb, Inc. | Apparatus and methods of milling a restricted casing shoe |
US7476517B2 (en) | 1999-06-30 | 2009-01-13 | Evotec Ag | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
WO2012083445A1 (en) | 2010-12-22 | 2012-06-28 | Medicago Inc. | Virus like particle production in plants |
CN102533680A (en) * | 2011-06-24 | 2012-07-04 | 武汉生物制品研究所有限责任公司 | Virus-like particles for pseudorabies virus and preparation method for same |
WO2012171104A1 (en) | 2011-06-13 | 2012-12-20 | Medicago Inc. | Rabies virus like particle production in plants |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987002058A1 (en) * | 1985-10-04 | 1987-04-09 | The Upjohn Company | Pseudorabies virus protein |
EP0256677A2 (en) * | 1986-07-18 | 1988-02-24 | E.I. Du Pont De Nemours And Company | Pseudorabies virus recombinants and their use in the production of proteins |
WO1990002566A1 (en) * | 1988-09-02 | 1990-03-22 | Molecular Engineering Associates, Inc. | Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2026826A6 (en) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Method for producing a subunit vaccine against the canine parvovirus and other related viruses. |
ES2026827A6 (en) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Method for producing a subunit vaccine against porcine parvovirus. |
GB9107631D0 (en) * | 1991-04-10 | 1991-05-29 | British Bio Technology | Proteinaceous particles |
JPH06500128A (en) * | 1991-05-08 | 1994-01-06 | シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン | Immune stimulating and immunoenhancing reconstituted influenza virosomes and vaccines containing the same |
-
1992
- 1992-07-17 CA CA002113572A patent/CA2113572A1/en not_active Abandoned
- 1992-07-17 WO PCT/AU1992/000363 patent/WO1993001833A1/en not_active Application Discontinuation
- 1992-07-17 EP EP92916278A patent/EP0595970A4/en not_active Withdrawn
- 1992-07-17 JP JP5502485A patent/JPH06509228A/en active Pending
- 1992-07-17 NZ NZ243611A patent/NZ243611A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987002058A1 (en) * | 1985-10-04 | 1987-04-09 | The Upjohn Company | Pseudorabies virus protein |
EP0256677A2 (en) * | 1986-07-18 | 1988-02-24 | E.I. Du Pont De Nemours And Company | Pseudorabies virus recombinants and their use in the production of proteins |
WO1990002566A1 (en) * | 1988-09-02 | 1990-03-22 | Molecular Engineering Associates, Inc. | Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof |
Non-Patent Citations (4)
Title |
---|
Proc. Natl. Acad. Sci. USA (PNASA6), Vol. 81(22), pages 7194-7198, issued 1984, WIKTOR et al., "Protection from rabies by vaccinia virus recombinant containing the rabies virus glycoprotein gene". * |
See also references of EP0595970A4 * |
Virology, Vol. 173(2) pages 390-399, issued 1989 (Oxford, UK) PREHAUD et al., "Immunogenic and protective of rabies virus glycoprotein expressed by baculovirus vectors". * |
Wistar Symp. Ser. (WSYSD3), Vol. 3, pages 259-267, issued 1985 (France) LECOCQ et al., "New rabies vaccine: recombinant DNA approaches". * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0672153A1 (en) * | 1992-09-28 | 1995-09-20 | Commonwealth Scientific And Industrial Research Organisation | Vector to deliver and express foreign gene |
EP0672153A4 (en) * | 1992-09-28 | 1997-05-07 | Commw Scient Ind Res Org | Vector to deliver and express foreign gene. |
US6818209B1 (en) | 1998-05-22 | 2004-11-16 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
WO1999061639A3 (en) * | 1998-05-22 | 2000-01-27 | Oxford Biomedica Ltd | Retroviral delivery system |
GB2351290A (en) * | 1998-05-22 | 2000-12-27 | Oxford Biomedica Ltd | Retroviral delivery sytem |
WO1999061639A2 (en) * | 1998-05-22 | 1999-12-02 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
US7419802B2 (en) | 1999-06-30 | 2008-09-02 | Evotec Ag | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
US7476517B2 (en) | 1999-06-30 | 2009-01-13 | Evotec Ag | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
EP1219705A1 (en) * | 2000-12-29 | 2002-07-03 | Evotec OAI AG | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
WO2008124636A1 (en) | 2007-04-04 | 2008-10-16 | Weatherford/Lamb, Inc. | Apparatus and methods of milling a restricted casing shoe |
WO2012083445A1 (en) | 2010-12-22 | 2012-06-28 | Medicago Inc. | Virus like particle production in plants |
WO2012171104A1 (en) | 2011-06-13 | 2012-12-20 | Medicago Inc. | Rabies virus like particle production in plants |
RU2655433C2 (en) * | 2011-06-13 | 2018-05-28 | Медикаго Инк. | Production of rabies virus-like particle in plants |
CN102533680A (en) * | 2011-06-24 | 2012-07-04 | 武汉生物制品研究所有限责任公司 | Virus-like particles for pseudorabies virus and preparation method for same |
CN102533680B (en) * | 2011-06-24 | 2014-03-26 | 武汉生物制品研究所有限责任公司 | Virus-like particles for pseudorabies virus and preparation method for same |
Also Published As
Publication number | Publication date |
---|---|
NZ243611A (en) | 1993-12-23 |
CA2113572A1 (en) | 1993-02-04 |
EP0595970A4 (en) | 1995-05-31 |
JPH06509228A (en) | 1994-10-20 |
EP0595970A1 (en) | 1994-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1644037B1 (en) | Functional influenza virus-like particles (vlps) | |
JP4704232B2 (en) | Recombinant infectious non-segmented negative-strand RNA virus | |
US8080255B2 (en) | Functional influenza virus like particles (VLPs) | |
EP1937301B1 (en) | Functional influenza virus like particles (vlps) | |
JPH11507510A (en) | A novel recombination temperature sensitive mutant of influenza | |
WO1993001833A1 (en) | Improved vaccine | |
IL143149A (en) | Stable, attenuated rabies virus mutants and live vaccines thereof | |
AU2366592A (en) | Improved vaccine | |
JP2002507408A (en) | Mutations responsible for attenuation of measles virus or human respiratory syncytial virus subgroup B | |
AU2011218606B2 (en) | Functional influenza virus-like particles (VLPS) | |
MXPA01005272A (en) | Stable, attenuated rabies virus mutants and live vaccines thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 1994 190176 Country of ref document: US Date of ref document: 19940113 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2113572 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992916278 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992916278 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992916278 Country of ref document: EP |